CL2019002810A1 - Compuestos inhibidores de ask1 y usos de los mismos. - Google Patents
Compuestos inhibidores de ask1 y usos de los mismos.Info
- Publication number
- CL2019002810A1 CL2019002810A1 CL2019002810A CL2019002810A CL2019002810A1 CL 2019002810 A1 CL2019002810 A1 CL 2019002810A1 CL 2019002810 A CL2019002810 A CL 2019002810A CL 2019002810 A CL2019002810 A CL 2019002810A CL 2019002810 A1 CL2019002810 A1 CL 2019002810A1
- Authority
- CL
- Chile
- Prior art keywords
- trodheutices
- inhibitor compounds
- solvates
- ask1 inhibitor
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Abstract
EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPUESTOS, QUE INCLUYEN SALES, SOLVATOS, METABOLITOS, PROFÁRMACOS FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, MÉTODOS PARA PREPARAR TALES COMPUESTOS, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS Y MÉTODOS PARA USAR DICHOS COMPUESTOS PARA TRATAR LA ESTEATOHEPATITIS NO ALCOHÓLICA Y OTRAS ENFERMEDADES CARACTERIZADAS POR LA CURACIÓN DISFUNCIONAL DEL TEJIDO Y FIBROSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002810A1 true CL2019002810A1 (es) | 2020-03-27 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002810A CL2019002810A1 (es) | 2017-04-05 | 2019-10-02 | Compuestos inhibidores de ask1 y usos de los mismos. |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20210087167A1 (es) |
| EP (1) | EP3606519B1 (es) |
| JP (1) | JP7196093B2 (es) |
| KR (1) | KR102665145B1 (es) |
| CN (1) | CN110730661B (es) |
| AR (1) | AR111407A1 (es) |
| AU (1) | AU2018250217B2 (es) |
| CA (1) | CA3059107A1 (es) |
| CL (1) | CL2019002810A1 (es) |
| CO (1) | CO2019011708A2 (es) |
| CR (1) | CR20190503A (es) |
| CU (1) | CU20190080A7 (es) |
| DK (1) | DK3606519T3 (es) |
| DO (1) | DOP2019000255A (es) |
| EA (1) | EA201992299A1 (es) |
| EC (1) | ECSP19078393A (es) |
| ES (1) | ES2992084T3 (es) |
| FI (1) | FI3606519T3 (es) |
| HU (1) | HUE068103T2 (es) |
| IL (1) | IL269711B (es) |
| JO (1) | JOP20190221A1 (es) |
| MA (1) | MA49047A (es) |
| MX (1) | MX394098B (es) |
| NI (1) | NI201900102A (es) |
| NZ (1) | NZ758345A (es) |
| PE (1) | PE20200009A1 (es) |
| PH (1) | PH12019502288A1 (es) |
| PL (1) | PL3606519T3 (es) |
| PT (1) | PT3606519T (es) |
| RU (1) | RU2019134679A (es) |
| SG (1) | SG11201909155VA (es) |
| SI (1) | SI3606519T1 (es) |
| TW (1) | TWI779022B (es) |
| WO (1) | WO2018187506A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019136025A1 (en) | 2018-01-02 | 2019-07-11 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019213244A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) * | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| AU2020412429B2 (en) | 2019-12-27 | 2025-12-04 | Lupin Limited | Substituted tricyclic compounds |
| WO2021220185A1 (en) | 2020-05-01 | 2021-11-04 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| EP4188549A1 (en) * | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2025525586A (ja) * | 2022-07-20 | 2025-08-05 | シール ロック セラピューティクス，インク． | 器官の疾患または障害をａｓｋ１阻害剤で処置する方法 |
| WO2025233319A1 (en) | 2024-05-06 | 2025-11-13 | Genfit | (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| CN102834393B (zh) * | 2010-02-03 | 2015-07-22 | 武田药品工业株式会社 | 细胞凋亡信号调节激酶1抑制剂 |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| ES2617339T3 (es) * | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| BR112017005693A2 (pt) * | 2014-09-24 | 2017-12-12 | Gilead Sciences Inc | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. |
| US10669242B2 (en) * | 2016-06-10 | 2020-06-02 | Venenum Biodesign, LLC | Clostridium difficile toxin inhibitors |
| JP6754505B2 (ja) | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| AU2018209574B2 (en) | 2017-01-22 | 2021-04-08 | Fujian Akeylink Biotechnology Co., Ltd. | Pyridine derivative as ASK1 inhibitor and preparation method and use thereof |
| ES2926449T3 (es) | 2017-02-07 | 2022-10-26 | Biogen Ma Inc | Agentes inhibidores de ASK1 |
| CN109071498B (zh) | 2017-02-16 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| TW201833108A (zh) | 2017-03-03 | 2018-09-16 | 大陸商江蘇豪森藥業集團有限公司 | 醯胺類衍生物抑制劑及其製備方法和應用 |
| JP2020512976A (ja) | 2017-03-27 | 2020-04-30 | ファーマケア，インク． | アポトーシスシグナル調節キナーゼ１（ａｓｋ１）阻害剤化合物 |
| WO2019055540A1 (en) * | 2017-09-13 | 2019-03-21 | D.E. Shaw Research, Llc | COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE |
| US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 HU HUE18780760A patent/HUE068103T2/hu unknown
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 SI SI201831140T patent/SI3606519T1/sl unknown
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en not_active Ceased
- 2018-04-04 PL PL18780760.7T patent/PL3606519T3/pl unknown
- 2018-04-04 ES ES18780760T patent/ES2992084T3/es active Active
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active Active
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 MX MX2019012013A patent/MX394098B/es unknown
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/en active Active
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es active IP Right Grant
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
-
2024
- 2024-09-26 US US18/897,798 patent/US20250304552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| CO2019007129A2 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| MX2019003887A (es) | Compuestos, dispositivos y usos de los mismos. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| MX2018001721A (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer. | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2017001124A1 (es) | Agentes inmunomoduladores | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| CL2020002624A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR111063A1 (es) | Dendrímeros terapéuticos |